Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Appili Therapeutics Inc (APLI.TO)

Appili Therapeutics Inc (APLI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 2,425
  • Shares Outstanding, K 121,266
  • Annual Sales, $ 100 K
  • Annual Income, $ -2,625 K
  • EBIT $ N/A
  • EBITDA $ N/A
  • 60-Month Beta 0.01
  • Price/Sales 12.15
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.02
  • Most Recent Earnings $-0.01 on 11/13/25
  • Next Earnings Date 02/18/25
  • Annual Dividend & Yield (Fwd) N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING:

    SIC-2834 Pharmaceutical Preparations

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0200 unch
on 01/16/26
0.0250 -20.00%
on 01/14/26
-0.0050 (-20.00%)
since 12/15/25
3-Month
0.0200 unch
on 01/16/26
0.0300 -33.33%
on 12/08/25
-0.0100 (-33.33%)
since 10/16/25
52-Week
0.0100 +100.00%
on 09/22/25
0.0450 -55.56%
on 02/19/25
-0.0200 (-50.00%)
since 01/16/25

Most Recent Stories

More News
Appili Therapeutics Announces Closing of First Tranche of Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2026

New NIAID Non-Dilutive Funding Award of up to US $40Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs LIKMEZ® (ATI-1501): Building Commercial Momentum in...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics Announces Proposed Non-Brokered Private Placement

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES HALIFAX, Nova Scotia, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF)...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics to Attend BARDA Innovation Symposium 2025

HALIFAX, Nova Scotia, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTC Pink: APLIF) (“Appili” or the “Company”) today announced that it will attend the Biomedical Advanced...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Stocks in play: Appili Therapeutics Inc.

And its partner Vitalex Biosciences today announced that the National Institute of Allergy and Infectious ...

APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics and its Partner Vitalex Biosciences Awarded Contract from NIAID Valued at up to US$40 Million to Develop Fungal Vaccine VXV-01

Awarded contract base period of US$3.6 million to fund vaccine manufacturing with additional option periods to advance development through Phase 1 trials Submitted up to US$97 million in additional...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

HALIFAX, Nova Scotia, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “ Company ” or “ Appili ”), a biopharmaceutical company focused on drug development...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics to Present Progress on Tularemia Biodefense Vaccine at NATO CBRN Conference

HALIFAX, Nova Scotia, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2026

Submitted two additional U.S. government funding proposals during the quarter, bringing the total proposals to US$137 million Accepted as a new member of U.S. Medical CBRN Defense Consortium, strengthening...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)
Appili Therapeutics and Colleagues Publish Manuscript Demonstrating Efficacy of ATI-1701 Tularemia Vaccine

Peer-reviewed publication highlights ATI-1701’s robust protection against aerosolized Francisella tularensis exposure in multiple animal models HALIFAX, Nova Scotia, Aug. 06, 2025 (GLOBE NEWSWIRE)...

APLIF : 0.0171 (+15.54%)
APLI.TO : 0.0200 (-20.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes programs namely ATI-1701, ATI-1801.

See More

Key Turning Points

3rd Resistance Point 0.0200
2nd Resistance Point 0.0200
1st Resistance Point 0.0200
Last Price 0.0200
1st Support Level 0.0200
2nd Support Level 0.0200
3rd Support Level 0.0200

See More

52-Week High 0.0450
Fibonacci 61.8% 0.0316
Fibonacci 50% 0.0275
Fibonacci 38.2% 0.0234
Last Price 0.0200
52-Week Low 0.0100

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar